Telemedicine for Sickle Cell Anemia
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to learn more about how the use of two different types of telemedicine (distance medical care) can address barriers to receiving comprehensive sickle cell care, and whether care can be improved. Aim 1: Adapt two telemedicine models (i.e., hub-and-spoke; direct-to-consumer) for use with children with SCD using caregiver input from our preliminary K12 work. Aim 2: Demonstrate the feasibility of the telemedicine models developed in Aim 1 as the models undergo successive stakeholder refinement during use in actual clinical care. Aim 3: Evaluate the effectiveness of the refined models from Aim 2 in a pre/post study by assessing (a) process of care measures, (b) provider satisfaction, (c) caregiver/patient-centered outcomes, and (d) clinical outcomes and healthcare utilization.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are on chronic transfusion therapy, you cannot participate in this trial.
Is telemedicine safe for use in humans?
How does telemedicine treatment for sickle cell anemia differ from other treatments?
Telemedicine for sickle cell anemia is unique because it allows patients to access healthcare remotely, which can be especially beneficial for those in rural or underserved areas who face barriers to in-person care. This approach provides regular follow-up and acute care evaluations without the need for travel, making it more convenient and accessible compared to traditional in-person visits.23567
What data supports the effectiveness of telemedicine as a treatment for sickle cell anemia?
Research shows that telemedicine can improve access to care for sickle cell patients, especially in rural areas, by increasing the number of medical encounters without needing more staff. This suggests telemedicine can help manage sickle cell disease effectively by making it easier for patients to receive regular care.23589
Who Is on the Research Team?
Seethal Jacob, MD
Principal Investigator
Indiana University
Are You a Good Fit for This Trial?
This trial is for caregivers over 18 with children (0-21 years) diagnosed with Sickle Cell Disease at Riley Hospital's clinic. Adolescents aged 16+ can also join. Participants must be willing to use telemedicine based on where they live, with specific distance criteria for different models.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Adaptation and Feasibility
Adaptation of telemedicine models and demonstration of feasibility with stakeholder refinement
Evaluation
Evaluation of the effectiveness of telemedicine models in a pre/post study
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Types of Telemedicine Delivery Models
Types of Telemedicine Delivery Models is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Indiana University
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator